Trial | NCT02647515  Report issue

Title

Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    18
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.
Study Started
Jan 31
2013
Primary Completion
Dec 31
2014
Study Completion
Dec 31
2014
Last Update
Jan 06
2016
Estimate

Drug ranibizumab

ranibizumab Experimental

Criteria 

Inclusion Criteria:

age≥18 years
PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions
NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle)

Exclusion Criteria:

intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy
previous intravitreal injection of ranibizumab or bevacizumab in either eye
previous intravitreal corticosteroids injection in either eye
pregnancy or current oral contraceptive intake
usage of clopidogrel bisulfate or coumadin
uncontrolled hypertension and cardiac disease
uncontrolled renal or liver disease
No Results Posted